Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03182959 | Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer | completed | Early Phase 1 | 6 | University of ArizonaOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02544880 | PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC | completed | Phase 1 | 16 | Donald T. Weed, MD, FACSOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT01427478 | Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck(BIBW2992ORL) | completed | Phase 3 | 134 | Centre Leon BerardOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04270201 | Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population(ALDH2020) | unknown | — | 300 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04882462 | Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.(Carpp-1) | unknown | Phase 2 | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | May 12, 2021 | clinicaltrials |
| NCT03673735 | Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC(ADHERE) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 10, 2021 | clinicaltrials |
| NCT02762513 | Expansion Trial for Axitinib In Head And Neck Cancer | completed | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT03134846 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate(ICON) | unknown | Phase 1 / Phase 2 | 79 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04861467 | Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 155 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer | terminated | N/A | 8 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02537223 | Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer | completed | Phase 1 | 9 | University Health Network, TorontoOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04523883 | Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)(IMPORT) | unknown | Phase 2 | 316 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT02661152 | DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.(DAHANCA30) | unknown | Phase 3 | 1,252 | Danish Head and Neck Cancer GroupNETWORK | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04196985 | 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC(HENEPET) | unknown | N/A | 40 | Turku University HospitalOTHER_GOV | 1 | Apr 13, 2021 | clinicaltrials |
| NCT03194373 | Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 21 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT00896181 | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 26 | Stanford UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04832555 | Non Elective Vulnerable Elderly Radiotherapy(NEVER) | unknown | N/A | 100 | Azienda Ospedaliero Universitaria Policlinico ModenaOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826679 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | unknown | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04098458 | Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC | completed | N/A | 18 | Medical University of South CarolinaOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT03144778 | Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer | completed | Phase 1 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT03771820 | Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | unknown | Phase 2 | 136 | NanoCarrier Co., Ltd.INDUSTRY | 8 | Mar 17, 2021 | clinicaltrials |
| NCT02054442 | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck(COMMENCE) | unknown | Phase 1 / Phase 2 | 52 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT00084682 | Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2021 | clinicaltrials |
| NCT04780750 | Concurent Chemoradiotherapy in Head and Neck Cancers | unknown | Phase 3 | 60 | Assiut UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT04766827 | Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor | unknown | Phase 4 | 116 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04440917 | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma(IMplus) | unknown | Phase 2 | 32 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT01663259 | Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients | completed | N/A | 43 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT01414426 | Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | completed | Phase 2 | 20 | University of ChicagoOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT02794675 | Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer | completed | Early Phase 1 | 15 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT01598077 | A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer | completed | Phase 1 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT00210470 | A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer | completed | Phase 2 | 27 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 0 | Dec 11, 2020 | clinicaltrials |
| NCT01689194 | Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer | completed | Phase 2 | 53 | Seoul National University HospitalOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02025062 | Comprehensive Geriatric Assessment and Head and Neck Elderly Cancer Patients(EGéSOR) | completed | N/A | 499 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01386632 | Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma | completed | Phase 2 | 50 | Sanford HealthOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT03276819 | A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC(UMBRELLA) | terminated | N/A | 53 | Centre Leon BerardOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04543266 | Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning | unknown | — | 500 | The University of Hong KongOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00736944 | Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer | completed | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04279509 | Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) | unknown | N/A | 35 | National University Hospital, SingaporeOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04220749 | Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | withdrawn | Phase 2 | 0 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2020 | clinicaltrials |
| NCT04525066 | Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma | completed | Phase 2 | 39 | Ayhman Al AfifOTHER | 0 | Aug 25, 2020 | clinicaltrials |
| NCT02464137 | HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer(HYDRA) | terminated | Phase 1 | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 21, 2021source: clinicaltrials